作者: Norman E. Sharpless , Ronald A. DePinho
DOI: 10.1038/NRD2110
关键词:
摘要: Deficiencies in the standard preclinical methods for evaluating potential anticancer drugs,such as xenograft mouse models, have been highlighted a key obstacle translation of major advances basic cancer research into meaningful clinical benefits. In this article, we discuss established uses and limitations models drug development, then describe opportunities challenges application novel genetically engineered that more faithfully mimic genetic biological evolution human cancers. Greater use such target validation, assessment tumour response, investigation pharmacodynamic markers action, modelling resistance understanding toxicity has to markedly improve success development.